Diagnostic accuracy of serum glypican-3 for hepatocellular carcinoma: A systematic review and meta-analysis

Clinical Biochemistry

Volumn 47, Issue 3, 2014, Pages 196-200

  Liu, Xiao Fei ^a   Hu, Zhi De ^a   Liu, Xiao Cui ^b   Cao, Yuan ^a   Ding, Chun Mei ^a   Hu, Cheng Jin ^a  

^a General Hospital of Ji'nan Military Region   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Diagnostic value; Glypican 3; Hepatocellular carcinoma; Systematic review

Indexed keywords

DIAGNOSTIC VALUE; GLYPICAN-3; HEPATOCELLULAR CARCINOMA; SYSTEMATIC REVIEW;

CARCINOMA, HEPATOCELLULAR; FEMALE; GLYPICANS; HUMANS; LIVER NEOPLASMS; MALE; SENSITIVITY AND SPECIFICITY;

EID: 84893746921     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2013.12.007     Document Type: Article

References (42)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Kawano Y., Sasaki A., Kai S., Endo Y., Iwaki K., Uchida H., et al. Short- and long-term outcomes after hepatic resection for hepatocellular carcinoma with concomitant esophageal varices in patients with cirrhosis. Ann Surg Oncol 2008, 15:1670-1676.
3. Stefaniuk P., Cianciara J., Wiercinska-Drapalo A. Present and future possibilities for early diagnosis of hepatocellular carcinoma. World J Gastroenterol 2010, 16:418-424.
4. Marrero J.A., Lok A.S. Newer markers for hepatocellular carcinoma. Gastroenterology 2004, 127:S113-S119.
5. Sherman M., Klein A. Aasld single-topic research conference on hepatocellular carcinoma: conference proceedings. Hepatology 2004, 40:1465-1473.
6. Bertino G., Ardiri A., Malaguarnera M., Malaguarnera G., Bertino N., Calvagno G.S. Hepatocellular carcinoma serum markers. Semin Oncol 2012, 39:410-433.
7. Filmus J., Selleck S.B. Glypicans: proteoglycans with a surprise. J Clin Invest 2001, 108:497-501.
8. Zhu Z.W., Friess H., Wang L., Abou-Shady M., Zimmermann A., Lander A.D., et al. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut 2001, 48:558-564.
9. Zhang L., Liu H., Sun L., Li N., Ding H., Zheng J. Glypican-3 as a potential differential diagnosis marker for hepatocellular carcinoma: a tissue microarray-based study. Acta Histochem 2012, 114:547-552.
10. Llovet J.M., Chen Y., Wurmbach E., Roayaie S., Fiel M.I., Schwartz M., et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 2006, 131:1758-1767.
11. Wang X.Y., Degos F., Dubois S., Tessiore S., Allegretta M., Guttmann R.D., et al. Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum Pathol 2006, 37:1435-1441.
12. Capurro M., Wanless I.R., Sherman M., Deboer G., Shi W., Miyoshi E., et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003, 125:89-97.
13. Whiting P.F., Rutjes A.W., Westwood M.E., Mallett S., Deeks J.J., Reitsma J.B., et al. Quadas-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011, 155:529-536.
14. Deville W.L., Buntinx F., Bouter L.M., Montori V.M., de Vet H.C., van der Windt D.A., et al. Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol 2002, 2:9.
15. Zamora J., Abraira V., Muriel A., Khan K., Coomarasamy A. Meta-disc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 2006, 6:31.
16. Moses L.E., Shapiro D., Littenberg B. Combining independent studies of a diagnostic test into a summary roc curve: data-analytic approaches and some additional considerations. Stat Med 1993, 12:1293-1316.
17. Walter S.D. Properties of the summary receiver operating characteristic (sROC) curve for diagnostic test data. Stat Med 2002, 21:1237-1256.
18. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
19. Suzuki M., Sugimoto K., Tanaka J., Tameda M., Inagaki Y., Kusagawa S., et al. Up-regulation of glypican-3 in human hepatocellular carcinoma. Anticancer Res 2010, 30:5055-5061.
20. Nakatsura T., Yoshitake Y., Senju S., Monji M., Komori H., Motomura Y., et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003, 306:16-25.
21. Hippo Y., Watanabe K., Watanabe A., Midorikawa Y., Yamamoto S., Ihara S., et al. Identification of soluble nh2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res 2004, 64:2418-2423.
22. Beale G., Chattopadhyay D., Gray J., Stewart S., Hudson M., Day C., et al. Afp, pivkaii, gp3, scca-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease. BMC Cancer 2008, 8:200.
23. Liu H., Li P., Zhai Y., Qu C.F., Zhang L.J., Tan Y.F., et al. Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma. World J Gastroenterol 2010, 16:4410-4415.
24. Tangkijvanich P., Chanmee T., Komtong S., Mahachai V., Wisedopas N., Pothacharoen P., et al. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers. J Gastroenterol Hepatol 2010, 25:129-137.
25. Yasuda E., Kumada T., Toyoda H., Kaneoka Y., Maeda A., Okuda S., et al. Evaluation for clinical utility of gpc3, measured by a commercially available elisa kit with glypican-3 (gpc3) antibody, as a serological and histological marker for hepatocellular carcinoma. Hepatol Res 2010, 40:477-485.
26. Youssef M.F., El-Sharkawy S.L., Abbas N.F., El-Shinnawy S.E., El-Hadidi E.S., Shahin R.S., et al. Clinical utility of glypican-3 in hepatocellular carcinoma. Int J Integr Biol 2010, 10:41-47.
27. Zhang Q., Xiao Q., Lin Z., Ying X., Li Z., Lin J.-M. Development of a competitive radioimmunoassay for glypican-3 and the clinical application in diagnosis of hepatocellular carcinoma. Clin Biochem 2010, 43:1003-1008.
28. Ozkan H., Erdal H., Kocak E., Tutkak H., Karaeren Z., Yakut M., et al. Diagnostic and prognostic role of serum glypican 3 in patients with hepatocellular carcinoma. J Clin Lab Anal 2011, 25:350-353.
29. Qiao S.S., Cui Z.Q., Gong L., Han H., Chen P.C., Guo L.M., et al. Simultaneous measurements of serum AFP, GPC-3 and HCCR for diagnosing hepatocellular carcinoma. Hepatogastroenterology 2011, 58:1718-1724.
30. Wang W., Zhao L.J., Wang Y., Tao Q.Y., Feitelson M.A., Zhao P., et al. Application of HBx-induced anti-URGs as early warning biomarker of cirrhosis and HCC. Cancer Biomark 2012, 11:29-39.
31. Bossuyt P.M., Reitsma J.B., Bruns D.E., Gatsonis C.A., Glasziou P.P., Irwig L.M., et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin Chem 2003, 49:7-18.
32. Cleophas T.J., Zwinderman A.H. Meta-analyses of diagnostic studies. Clin Chem Lab Med 2009, 47:1351-1354.
33. Glas A.S., Lijmer J.G., Prins M.H., Bonsel G.J., Bossuyt P.M. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol 2003, 56:1129-1135.
34. Malaguarnera G., Giordano M., Paladina I., Berretta M., Cappellani A., Malaguarnera M. Serum markers of hepatocellular carcinoma. Dig Dis Sci 2010, 55:2744-2755.
35. Zhou L., Liu J., Luo F. Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol 2006, 12:1175-1181.
36. Zhou Y., Yin X., Ying J., Zhang B. Golgi protein 73 versus alpha-fetoprotein as a biomarker for hepatocellular carcinoma: a diagnostic meta-analysis. BMC Cancer 2012, 12:17.
37. Masuzaki R., Karp S.J., Omata M. New serum markers of hepatocellular carcinoma. Semin Oncol 2012, 39:434-439.
38. Pencina M.J., D'Agostino R.B., D'Agostino R.B., Vasan R.S. Evaluating the added predictive ability of a new marker: from area under the roc curve to reclassification and beyond. Stat Med 2008, 27:157-172. [discussion 207-12].
39. Pencina M.J., D'Agostino R.B., Vasan R.S. Statistical methods for assessment of added usefulness of new biomarkers. Clin Chem Lab Med 2010, 48:1703-1711.
40. Whiting P., Rutjes A.W., Reitsma J.B., Glas A.S., Bossuyt P.M., Kleijnen J. Sources of variation and bias in studies of diagnostic accuracy: a systematic review. Ann Intern Med 2004, 140:189-202.
41. Dalal B.I., Brigden M.L. Factitious biochemical measurements resulting from hematologic conditions. Am J Clin Pathol 2009, 131:195-204.
42. Lippi G., Blanckaert N., Bonini P., Green S., Kitchen S., Palicka V., et al. Haemolysis: an overview of the leading cause of unsuitable specimens in clinical laboratories. Clin Chem Lab Med 2008, 46:764-772.